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Background. Fluid resuscitation following traumatic injury causes haemodilution and can
contribute to coagulopathy. Coagulation factor replacement may be necessary to prevent
bleeding complications of dilutional coagulopathy. Compared with fresh frozen plasma (FFP),
prothrombin complex concentrate (PCC) may potentially offer a more rapid and effective
means of normalizing coagulation factor levels.
Methods. In anaesthetized mildly hypothermic pigs, 65–70% of total blood volume was substi-
tuted in phases with hydroxyethyl starch and red cells. Animals were then treated with 15 ml
kg
21 isotonic saline placebo, 25 IU kg
21 PCC, or 15 ml kg
21 FFP. Immediately thereafter,
either a standardized femur or spleen injury was inﬂicted, and coagulation function, including
thrombin generation, and bleeding were assessed. An additional group received high-dose FFP
(40 ml kg
21) before femur injury.
Results. Haemodilution markedly prolonged prothrombin time and reduced peak thrombin
generation. PCC, but not FFP, fully reversed those effects. Compared with 15 ml kg
21 FFP,
PCC shortened the time to haemostasis after either bone (P¼0.001) or spleen (P¼0.028)
trauma and reduced the volume of blood lost (P,0.001 and P¼0.015, respectively).
Subsequent to bone injury, PCC also accelerated haemostasis (P¼0.003) and diminished blood
loss (P¼0.006) vs 40 ml kg
21 FFP.
Conclusions. PCC was effective in correcting dilutional coagulopathy and controlling bleeding
in an in vivo large-animal trauma model. In light of its suitability for more rapid administration
than FFP, PCC merits further investigation as a therapy for dilutional coagulopathy in trauma
and surgery.
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Uncontrolled bleeding associated with major trauma and
surgery is often life-threatening. Acquired coagulopathy of
trauma is responsible for the majority of postoperative
traumatic haemorrhagic fatalities, and the onset of acute
coagulopathy is associated with increased overall mor-
tality.
1 The coagulopathy of trauma is a manifestation of
the combined effects of blood loss and dilution, coagu-
lation factor and platelet consumption, hypothermic plate-
let dysfunction, acidosis-induced decreases in coagulation
factor activity, and ﬁbrinolysis.
2
A recognized complication of massive transfusion is
dilutional coagulopathy, which occurs when lost blood is
replaced with ﬂuids that do not contain coagulation
factors. Dilutional coagulopathy is distinct from the more
recently recognized phenomenon of acute traumatic coagu-
lopathy, which is independent of i.v. ﬂuid administration
and appears to be mediated through activation of the
protein C pathway.
3 The shift from whole blood transfu-
sion in the past to the current practice of speciﬁc blood
component therapy has resulted in earlier occurrence of
thrombocytopenia and clotting factor deﬁciency in trauma
patients.
45Trauma resuscitation usually starts with crystal-
loid or colloid solutions followed by red blood cell
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2 A
vicious cycle can ensue, in which further haemorrhage
necessitates additional resuscitation ﬂuid with resultant
exacerbation of haemodilution, coagulopathy, and blood
loss. A recent German analysis demonstrated a high fre-
quency of established coagulopathy in multiple injury
patients upon emergency room admission that was associ-
ated with the amount of prior i.v. ﬂuids administered.
6
Consequently, a treatment strategy of earlier coagulation
factor replacement has been advocated.
478
Fresh frozen plasma (FFP) is a source of all the coagu-
lation factors, including the labile factors, and its use has
been recommended either in massive bleeding or signiﬁ-
cant bleeding complicated by coagulopathy, as indicated
by .1.5-fold prolongation of prothrombin time (PT) and
activated partial thromboplastin time (aPTT).
9 However,
FFP has certain drawbacks for rapid reversal of coagulo-
pathy. FFP may require ABO compatibility, and is typically
available only after the blood type has been established
and plasma has been thawed. These preliminary pro-
cedures may take more than an hour in some facilities and
may jeopardize the opportunity to prevent rapid deterio-
ration in the clinical condition of the patient.
2 Although
the overall risks of FFP are low, complications can include
immunological reactions such as allergy/anaphylaxis,
transfusion-related acute lung injury (TRALI), and haemo-
lysis due to anti-A or anti-B if FFP is transfused across
ABO groups.
10 11 TRALI, an acute syndrome of dyspnoea,
hypoxia, and pulmonary ‘white-out’, is a major cause of
transfusion-related death.
10
Delivery of coagulation factors in concentrated form may
offer advantages in overcoming the coagulopathic effects
of large resuscitation ﬂuid volumes.
2 Prothrombin complex
concentrate (PCC), which contains vitamin K-dependent
coagulation factors, can be administered rapidly without the
need for matching the blood group or thawing the product.
PCC has increasingly been employed for rapid reversal of
coumarin oral anticoagulant therapy.
12–21 The most recent
update from the British Committee for Standards in
Haematology recommends that, for reversal of anticoagula-
tion in patients with major bleeding, PCC should be admi-
nistered in preference to FFP.
22 The use of PCC in trauma
patients has not been reported.
In coagulopathic trauma patients, a major obstacle to
optimal coagulation factor replacement therapy has been
the lack of suitable assays that can reﬂect the overall haemo-
static balance. The calibrated automated thrombin gener-
ation assay (TGA) is a global coagulation test being used
to monitor both hypocoagulable and hypercoagulable
states. Thrombin generation, which plays a central role in
activating coagulation enzymes, inhibitors, and platelets
and in cleaving ﬁbrinogen to ﬁbrin monomers, has been
proposed as an overall function test of the haemostatic–
thrombotic system.
23 Thrombin generation has been inves-
tigated as a means to monitor treatment with bypassing
agents such as factor VIII inhibitor bypass activity
(FEIBA), which is an activated PCC, and recombinant
factor VIIa in haemophilia patients with inhibitors.
24–27
PCC-mediated oral anticoagulant reversal in vitro has
recently been evaluated using TGA.
28
An animal model of dilutional coagulopathy and major
haemorrhage in pigs has been developed.
29 In that study,
PCC was effective in normalizing coagulation and improv-
ing haemostasis compared with an inactive placebo;
however, an active control ﬂuid containing coagulation
factors was not evaluated. The model was used in the
present study to compare the effects of PCC and FFP on
haemorrhage after femur or spleen injury. In addition, the
impact of those agents on coagulation function in vivo,
including thrombin generation, was examined.
Methods
Animals
As described previously in detail, dilutional coagulopathy
was induced in anaesthetized mildly hypothermic
(368C) pigs.
29 Forty-seven castrated male pigs (large
whiteGerman noble) were obtained from a local breed-
ing farm (Schlosser, Schwalmtal, Germany). The animals
were 3–4 months old and weighed 21–32 kg. The study
was performed in accordance with the German Animal
Welfare law and approved by the regional government
authorities. Animal housing and care were furnished in
compliance with current regulations of the European
Union.
Anaesthesia
After an overnight fast with free access to water, pigs
were premedicated i.m. with a mixture of 2 mg kg
21 azaper-
one (Stresnil
w, Janssen-Cilag GmbH, Neuss, Germany), 15
mg kg
21 ketamine (Ketavet, Pharmacia & Upjohn,
Erlangen, Germany), and 0.02 mg kg
21 atropine sulfate
(Atropinsulfate, B. Braun, Melsungen, Germany).
Anaesthesia was induced by 10 mg kg
21 thiopental sodium
via an ear vein. The animals were placed on a Heyer Access
ventilator after tracheal intubation. Inhaled anaesthesia was
maintained by isoﬂurane (Forane, Abbott Laboratories Inc.,
Abbott Park, IL, USA) at a concentration of 1–2%.
A 20-gauge catheter was placed into a femoral artery for
continuous arterial blood pressure measurements, and body
temperature was monitored by a rectal thermometer.
Attainment and maintenance of deep anaesthesia were
conﬁrmed by an absent pedal withdrawal reﬂex.
Haemodilution
Vascular access was secured through a 14-gauge catheter
in the external jugular vein. Phased blood withdrawal (total
60 ml kg
21, 65–70% of calculated total blood volume),
salvaged erythrocyte retransfusion (total 20 ml kg
21), and
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21 hydroxyethyl
starch 200/0.5 (Infukoll 6%, Schwarz Pharma AG,
Mannheim, Germany) were performed over a period of 80
min after induction of anaesthesia.
29
Treatment
Study treatments were administered 115 min after initiation
of blood withdrawal (25 min after completion of phased hae-
modilution). The pigs were randomly assigned to receive 15
ml kg
21 isotonic saline, 25 IU kg
21 PCC (Beriplex
w P/N,
CSL Behring GmbH, Marburg, Germany), or standard-dose
(15 ml kg
21) or high-dose (40 ml kg
21) porcine FFP via the
indwelling jugular catheter. The 40 ml kg
21 FFP dose was
selected to maximize efﬁcacy without unacceptable haemo-
dynamic disturbances. Beriplex P/N is a biochemically
well-characterized balanced PCC containing coagulation
factors II (FII), VII (FVII), IX (FIX), and X (FX), as well as
the anticoagulant proteins C and S.
30 The administered PCC
dose of 25 IU kg
21, based on FIX content, is equivalent to
0.8 ml kg
21.
The respective mean (SD) concentrations of FII, FVII,
FIX, and FX in Beriplex P/N are 31.0 (3.4), 16.2 (1.9),
28.9 (2.2), and 40.5 (3.3) IU ml
21.
31 Corresponding
values in porcine plasma are 0.50 (0.04), 0.48 (0.06), 2.3
(0.42), and 0.58 (0.07) U ml
21.
29 Therefore, the adminis-
tered 0.8 ml kg
21 PCC volume contained doses of those
coagulation factors, respectively, 3.3, 1.8, 0.67, and
3.7-fold those of the 15 ml kg
21 porcine PCC volume and
1.2, 0.68, 0.25, and 1.4-fold the 40 ml kg
21 volume.
Porcine rather than human FFP was selected as control
ﬂuid, because in pilot experiments unpredictable and
sometimes serious transfusion reactions were encountered
in pigs receiving human FFP. For preparation of porcine
FFP, blood was withdrawn from the carotid artery of
healthy donor pigs through custom-made connection
tubing. The anticoagulated blood was centrifuged 10 min
at 3000 g, and the plasma was frozen and stored at 2708C
until treatment. Prior to porcine FFP infusions, haemagglu-
tination and haemolysis of individual animal erythrocyte
specimens were tested to lessen the risk of transfusion
reactions.
Experimental trauma
At 5 min following administration of study treatments,
standardized wounds were created either by drilling a
3 mm hole into the femur or making a 7 cm long and 1
cm deep incision into the spleen. Time to haemostasis and
blood loss were monitored for 120 min after the exper-
imental injuries were inﬂicted. Groups of 5–7 pigs had
received each of the test treatments before femur injury.
Group size for spleen injury was six animals, with the
exception that seven animals had received saline placebo
prior to spleen incision.
Skin bleeding time (SBT) was determined in duplicate
from a 5 mm long and 1 mm deep incision at a shaved
inner site on the ear using a standard cutting device
(Surgicutt
w, International Technidyne Corp., Edison, NJ,
USA). Shed blood was blotted with a ﬁlter paper from the
edge of the wound. The time from incision to cessation of
blood ﬂow was recorded as the SBT. Determinations of
time to haemostasis, blood loss, and SBT were made by
observers blinded to the group assignments of the animals.
While remaining under deep anaesthesia, the animals were
humanely killed upon conclusion of the study experimen-
tal procedures by injecting embutramide, mebenzonium
iodide, and tetracaine hydrochloride (T61
w, Intervet
Deutschland GmbH, Unterschleißheim, Germany).
Laboratory assays
Blood samples were collected from the carotid artery at base-
line, after the completion of phased haemodilution (80 min)
and 5 min after study treatment administration (120 min).
Coagulation factors were measured in coagulation factor-
deﬁcient plasma (Dade Behring, Marburg, Germany) with a
Schnitger and Gross coagulometer (Heinrich Amelung
GmbH, Lemgo, Germany). FII, FVII, and FX were deter-
mined by PT assay, and FIX was measured by aPTT assay.
PT was determined with a Schnitger & Gross coagulometer
using the Thromborel reagent (Dade Behring).
TGA was performed by calibrated automated thrombi-
nography (CAT, Thrombinoscope B.V., Maastricht, the
Netherlands) in diluted plasma according to the method of
Hemker and colleagues.
32 The concentrations of recombi-
nant relipidated tissue factor (Dade Behring) and phospho-
lipids were 5 pM and 4 mM, respectively. The peak molar
quantity of thrombin present in clotting plasma was calcu-
lated using the Thrombinoscope software version 3.0.0.29.
Statistical analysis
Median differences and their 95% conﬁdence intervals
(CI) were determined by exact Hodges–Lehmann esti-
mation. Time to haemostasis was analysed by the
Kaplan–Meier product-limit method and exact logrank
test. Between-group differences in the volume of blood
lost were evaluated by exact Wilcoxon test. Analyses were
performed using R version 2.6.2 (The R Foundation for
Statistical Computing, Vienna, Austria) and StatXact 7.0
(Cytel Software Corp., Cambridge, MA, USA) statistical
software.
Results
Coagulation factors
Upon completion of phased haemodilution (80 min),
median rectal temperature fell to 36.28C with an interquar-
tile range (IQR) of 35.9–36.98C from 37.88C (IQR,
37.6–38.58C) at baseline. Haemodilution profoundly
diminished circulating concentrations of FII, FVII, FIX,
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(Fig. 1). The impact of standard- or high-dose FFP admin-
istration was minor, and all four coagulation factors
remained markedly lower than at baseline. In contrast,
PCC fully normalized FII, FVII, and FX. While the effect
was smaller, PCC did also increase FIX concentration
by a median of 7.8% (CI 6.4–9.4%) from the
post-haemodilution level.
Haemodilution was also attended by a major decrease in
circulating ﬁbrinogen concentration, from a median of
3.34 to 1.82 g litre
21 (Table 1). Nonetheless, ﬁbrinogen
level equalled or exceeded 1 g litre
21 in all animals
subsequent to haemodilution. After FFP or PCC admin-
istration, median ﬁbrinogen remained near the post-
haemodilution level. In no recipient of either FFP or PCC
did ﬁbrinogen level fall below 1 g litre
21.
Prothrombin time
Haemodilution prolonged PT (Fig. 2A). Saline adminis-
tration further lengthened PT, whereas FFP partially
reversed the haemodilution-induced PT prolongation. Of
the tested ﬂuids, PCC was the only one to normalize PT
fully.
Platelets
Platelet counts were markedly reduced by haemodilution.
The median value declined to 16110
9 litre
21 (IQR 138–
19710
9 litre
21) from 44410
9 litre
21 (IQR 374–
50610
9 litre
21) at baseline. Substantial depletion in
platelets persisted after administration of all test ﬂuids.
Thrombin generation
Haemodilution strongly attenuated peak thrombin gener-
ation (Fig. 2B). The haemodilution-induced decline in
peak thrombin generation was not reversed by either saline
or FFP (Fig. 2B). In contrast, PCC restored peak thrombin
generation to a level not signiﬁcantly different from that at
baseline.
Despite the observed attenuation of the thrombin peak,
the impact of haemodilution on endogenous thrombin
potential (ETP) was negligible (Fig. 2C). This observation
reﬂected the persistence of higher post-peak thrombin con-
centrations, thus offsetting the reduction in peak values.
The effects of saline and FFP on ETP were both minimal.
PCC, however, augmented ETP by a median of nearly
600 nM min above baseline.
Table 1 Fibrinogen. FFP, fresh frozen plasma; IQR, interquartile range; PCC,
prothrombin complex concentrate. *Fibrinogen concentration was not
determined in the placebo group. Baseline ﬁbrinogen was not evaluable for
one animal in the PCC group due to technical difﬁculties with the plasma
sample
Category n Fibrinogen (g litre
21), median (IQR)
Baseline 31* 3.34 (2.94–3.82)
Haemodilution 32 1.82 (1.52–2.04)
15 ml kg
21 FFP 14 2.04 (2.01–2.18)
40 ml kg
21 FFP 5 2.33 (2.26–2.37)
PCC 13 1.79 (1.54–1.91)
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FFP
15 ml kg
–1 40 ml kg
–1
Group Median change from baseline (CI)
15 ml kg
–1 FFP –46.0 (–49.7 to –42.3)
40 ml kg
–1 FFP –30.5 (–36.7 to –19.0)
PCC 30.8 (25.2 to 38.4)
Group Median change from baseline (CI)
15 ml kg
–1 FFP –52.6 (–57.6 to –45.4)
40 ml kg
–1 FFP –28.2 (–45.8 to –15.4)
PCC –5.9 (–15.1 to 4.1)
Group Median change from baseline (CI)
15 ml kg
–1 FFP –59.8 (–65.9 to –53.5)
40 ml kg
–1 FFP –43.1 (–53.3 to –36.1)
PCC –57.5 (–64.2 to –50.8)
Group Median change from baseline (CI)
15 ml kg
–1 FFP –60.0 (–66.6 to –55.3)
40 ml kg
–1 FFP –41.4 (–71.3 to –21.9)
PCC 14.7 (5.7 to 25.0)
Fig 1 Levels of (A) FII, (B) FVII, (C) FIX, and (D) FX at baseline and
after haemodilution and subsequent administration of FFP or PCC.
Concentration values expressed as a percentage of the baseline median.
In each panel is shown the median change from baseline in animals
receiving FFP and PCC and corresponding CI. Horizontal lines within
boxes indicate the medians, lower and upper box boundaries the 25th and
75th percentiles, respectively, and lower and upper error bars the 10th
and 90th percentiles. Individual animal data points and horizontal lines
representing the medians are displayed for the 40 ml kg
21 FFP group. CI,
95% conﬁdence interval; FFP, fresh frozen plasma; FII, factor II; FVII,
factor VII; FIX, factor IX; FX, factor X; PCC, prothrombin complex
concentrate.
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After either experimental bone or spleen trauma, PCC sig-
niﬁcantly shortened time to haemostasis compared with
FFP (Fig. 3). Haemostasis was achieved by all 13
PCC-treated animals. Over the course of the 120 min
observation period, bleeding failed to cease in four of 14
saline recipients (29%), ﬁve of 13 animals in the 15 ml
kg
21 FFP group (38%), and three of four evaluable pigs
(75%) treated with 40 ml kg
21 FFP. Compared with FFP,
PCC also signiﬁcantly lowered the volume of blood lost
following either bone or spleen trauma (Fig. 4).
From a baseline median of 117 s, SBT was more than
doubled by haemodilution (Table 2). Saline placebo and
FFP showed little effect in shortening the prolonged SBT.
However, PCC normalized SBT.
Discussion
Acquired coagulopathy following trauma is an important
determinant of outcome. Coagulopathic patients, including
those with head injury, experience worse outcomes than
patients with the same injury severity but no clotting
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Group Median change from baseline (CI)
Saline 7.1 (6.5 to 8.2)
15 ml kg–1 FFP 3.4 (2.8 to 3.9)
40 ml kg–1 FFP 1.6 (1.0 to 2.2)
PCC 0.9 (0.6 to 2.2)
Group Median change from baseline (CI)
Saline –38.7 (–42.6 to –36.2)
15 ml kg–1 FFP –32.7 (–35.6 to –30.5)
40 ml kg–1 FFP –23.4 (–28.9 to –17.9)
PCC 1.8 (–2.8 to 7.7)
Group Median change from baseline (CI)
Saline –38.5 (–69.5 to 0.2)
15 ml kg–1 FFP –15.2 (–33.2 to 1.5)
40 ml kg–1 FFP –40.0 (–87.5 to –6.0)
PCC 565.8 (529.3 to 605.3)
Fig 2 (A) Prothrombin time, (B) peak thrombin generation, and (C) ETP after haemodilution and subsequent administration of saline, FFP, or PCC.
Graphic conventions as in Figure 1. CI, 95% conﬁdence interval; FFP, fresh frozen plasma; ETP, endogenous thrombin potential; PCC, prothrombin
complex concentrate.
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349disturbance.
9 Therefore, a major clinical need exists for
modalities that quickly and effectively reverse the dilu-
tional coagulopathy occurring over the course of trauma
treatment. Pharmacological treatment options consist of
antiﬁbrinolytics, fresh whole blood and plasma, FFP,
cryoprecipitate, and coagulation factor concentrates.
293 3
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Fig 3 Time to haemostasis following experimental (A) bone or (B) spleen trauma in animals treated with saline, FFP, or PCC. FFP, fresh frozen
plasma; PCC, prothrombin complex concentrate.
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rection of coagulopathy under conditions of haemodilution
and haemorrhage in a porcine trauma model.
Time to haemostasis and blood loss following either
femur or spleen injury were both signiﬁcantly diminished
by PCC compared with FFP treatment. The ineffectiveness
of FFP with respect to these primary endpoints appears
to reﬂect persistent coagulation factor deﬁciency after
administration of a standard FFP dose (15 ml kg
21) com-
parable to the typical adult dose used in clinical practice,
as well as after a much higher dose (40 ml kg
21).
34 In the
absence of ongoing coagulation factor consumption or
loss, a dose of 10–15 ml kg
21 FFP is expected to raise
factor levels by 25% in humans.
33 In the porcine model,
smaller increases were observed, possibly due to the use
of human coagulation factor-deﬁcient plasma in the
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Fig 4 Individual animal blood losses following experimental (A) bone or (B) spleen trauma in groups treated with saline, FFP or PCC. Horizontal lines
depict the medians. FFP, fresh frozen plasma; PCC, prothrombin complex concentrate.
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species-speciﬁc coagulation factor-deﬁcient plasma would
be needed to assess the contribution, if any, of assay
method to the relatively small increases in coagulation
factor levels following FFP administration. On the other
hand, the normalization of FII, FVII, and FX levels by
PCC in the study animals suggests that assay inaccuracy
may not explain the lack of FFP effect in restoring levels
of those coagulation factors. In any case, high-dose FFP
proved to be no more effective than the standard dose in
speeding haemostasis and restricting blood loss after bone
injury.
In patients, greater restoration of coagulation factor
levels with FFP is hampered by the risk of ﬂuid overload.
Additionally, during preparation of FFP for clinical use,
coagulation factors are diluted by 15% with citrate, and
further losses are believed to occur during freezing and
thawing.
35 36 Due to the high coagulation factor concen-
trations in PCC, FII, FVII, and FX rebounded fully to
baseline levels after PCC administration in the model
system. The small FIX rise produced by PCC was similar
in magnitude to that by 15 ml kg
21 porcine FFP. This
observation reﬂects the comparatively low FIX dose in the
administered 0.8 ml kg
21 PCC volume. Whereas the doses
of the other three coagulation factors in the administered
PCC volume were 2–4-fold those in 15 ml kg
21 porcine
FFP, the corresponding dose of FIX was 33% lower. In
any case, PCC did produce a small but statistically signiﬁ-
cant increase in FIX which, in concert with full normaliza-
tion of the other three coagulation factors, proved
sufﬁcient to enhance haemostasis.
Another advantage of PCC is viral safety. Most FFP
preparations are not subjected to viral inactivation.
Prepared from plasma screened by polymerase chain reac-
tion, Beriplex P/N is pasteurized and nanoﬁltrated to elim-
inate viruses.
30 37 In clinical trials there has been no
evidence of viral transmission following Beriplex P/N
administration.
20 31
Although the coagulation factor increase was relatively
small, FFP did partially reverse the haemodilution-induced
PT prolongation. PCC, however, entirely normalized PT.
These ﬁndings are consistent with prior data. In a prospec-
tive audit of FFP transfusion in patients with mild PT pro-
longation (13–17 s), halfway normalization of PT was
accomplished in only 15% of cases and full correction in
,1%.
38 In contrast, Beriplex P/N administration effec-
tively normalized PT in critically ill patients with moder-
ately reduced coagulation activity.
39 In a porcine model of
dilutional coagulopathy similar to that in the present study,
PCC plus ﬁbrinogen normalized PT, while normal saline
was ineffective.
40
It is generally recognized that both PT and aPTT are
insensitive measures for detecting hypocoagulant con-
ditions.
36 The value of SBT in monitoring the coagulation
system and directing therapeutic inventions remains to be
established. In this study, the SBT results closely
coincided with those for time to haemostasis and volume
of blood loss after bone or spleen trauma. While platelet
function is a major determinant of SBT, the coagulation
cascade may also play a role. In rats, the direct thrombin
inhibitor melagatran has been shown to prolong SBT, and
the prolongation could be reversed by PCC.
41
TGAs are being actively investigated for their utility in
characterizing and monitoring both hypocoagulable and
hypercoagulable states. In the present study, TGA data
were consistent with the bleeding endpoint results. Thus,
PCC normalized the thrombin peak, whereas FFP had neg-
ligible effect.
TGA has been used to monitor the response to FFP
administration in surgery patients.
36 Thrombin generation
parameters and ﬁbrinogen levels were higher in post-
transfusion plasma from patients who stopped bleeding
than from those with ongoing haemorrhage. An in vitro
study has demonstrated the ability of PCC to restore
thrombin generation in plasma from orally anticoagulated
patients.
42 TGA has also been used to monitor the effects
of activated PCC.
25 43 44
Both platelet count and ﬁbrinogen concentration were
substantially reduced by haemodilution and did not
recover in response to PCC or FFP treatment. However,
the platelet number and ﬁbrinogen concentration were not
below the thresholds to sustain the competence of the
coagulation system, as demonstrated by the ability of PCC
to control femur and spleen bleeding.
The porcine model of dilutional coagulopathy employed
in the present study has been previously established for
evaluating the effectiveness of i.v. ﬂuids in normalizing
coagulation function and reducing bleeding resulting from
a subsequent haemorrhagic challenge in the form of a
standardized experimental femur or spleen injury.
29 The
model simulates clinical situations in which, after initial
traumatic haemorrhagic shock and resuscitation, haemo-
stasis has been secured, but dilutional coagulopathy needs
to be corrected to prevent excessive bleeding during
further surgical interventions the patient may require. A
similar porcine dilutional coagulopathy model has been
described, in which placebo or coagulation factors were
administered prior to a standardized hepatic laceration, and
subsequent blood loss and survival were assessed.
40
In this porcine trauma model of dilutional coagulopathy
and haemorrhage, PCC proved superior to FFP in
Table 2 Skin bleeding time. FFP, fresh frozen plasma; IQR, interquartile
range; PCC, prothrombin complex concentrate; SBT, skin bleeding time.
*One animal excluded due to the development of hypotension
Category n SBT (s), median (IQR)
Baseline 47 117 (108–127)
Haemodilution 47 305 (279–329)
Placebo 14 288 (273–311)
15 ml kg
21 FFP 15 250 (219–280)
40 ml kg
21 FFP 4* 234 (177–244)
PCC 13 137 (126–152)
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controlling bleeding. These ﬁndings support a potential
role for PCC in coagulopathic trauma and surgery patients.
In view of the unmet clinical need for more efﬁcacious
haemostatic agents in such patients, clinical studies are
now justiﬁed to conﬁrm the observed favourable effects of
PCC in the present preclinical model system.
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